Advice

Search strategy and evidence selection

Search strategy and evidence selection

Search strategy

Embase 1980 to 2014 Week 28, Ovid MEDLINE(R) In‑Process & Other Non‑Indexed Citations and Ovid MEDLINE(R) 1946 to Present; searched 18 July 2014

For clinical evidence:

1. nxstage.mp.

2. portable hemodialysis.mp.

3. home hemodialysis.mp. or Hemodialysis, Home/

4. home haemodialysis.mp.

5. purema.mp.

6. end stage renal disease.mp. or Kidney Failure, Chronic/

7. renal replacement therapy.mp. or Renal Replacement Therapy/

8. kidney failure.mp. or Renal Insufficiency/

9. 6 or 7 or 8

10. 1 or 2 or 3 or 4 or 5

11. 9 and 10

12. limit 11 to english language

13. limit 12 to human

14. limit 13 to yr="1998 ‑Current"

15. limit 14 to humans

16. remove duplicates from 15

The Cochrane and DARE databases were searched using the following keywords:

  • Any field: nxstage/OR

  • Any field: portable hemodialysis/OR

  • Any field: home hemodialysis

Evidence selection

  • Total number of publications reviewed: 791

  • Total number of publications considered relevant: 42 (27 full publications and 15 abstracts)

  • Total number of publications selected for inclusion in this briefing: 9 (8 full publication and 1 abstract)

  • Exclusion criteria: case studies, editorials, letters, reviews, animal studies, and non‑English language studies, not using the NxStage System One for renal replacement therapy.

For economic evidence:

1. end stage renal disease.mp. or Kidney Failure, Chronic/

2. renal replacement therapy.mp. or Renal Replacement Therapy/

3. kidney failure.mp. or Renal Insufficiency/

4. 1 or 2 or 3

5. nxstage.mp.

6. portable hemodialysis.mp.

7. home hemodialysis.mp. or Hemodialysis, Home/

8. home haemodialysis.mp.

9. purema.mp.

10. 5 or 6 or 7 or 8 or 9

11. cost*.mp.

12. economic*.mp.

13. 11 or 12

14. 4 and 10 and 13

15. limit 14 to yr="1998 ‑Current"

16. limit 15 to english language

17. limit 16 to humans

18. remove duplicates from 17

Cochrane Database of Systematic Reviews: Issue 7 of 12, July 2014

Cochrane Central Register of Controlled Trials: Issue 6 of 12, June 2014

#1 end stage renal disease or chronic kidney failure or renal replacement therapy or kidney failure or renal insufficiency

#2 nxstage or portable hemodialysis or home hemodialysis or purema

#3 cost* or economic*

#5 #1 and #2 and #3

DARE (Database of Abstracts of Reviews of Effects), NHS EED (National Health Service Economic Evaluation Database), and HTA (Health Technology Assessment) databases

(end stage renal disease or chronic kidney failure or renal replacement therapy or kidney failure or renal insufficiency) AND (nxstage or portable hemodialysis or home hemodialysis or purema) AND (cost or economic) IN DARE, NHSEED, HTA FROM 1998 TO 2014

Evidence selection (economic evidence)

  • Total number of full‑text publications considered relevant: 0

  • Total number of abstracts considered relevant: 262

  • Number of duplicated abstracts: 4

  • Total number of abstracts reviewed: 258

  • Total number of publications selected for inclusion in this briefing: 0

  • Exclusion criteria: case studies, editorials, letters, reviews, conference proceedings/abstracts, animal studies, non‑English language studies, not using the NxStage System One for renal replacement therapy.